Clorox Company — FY2023 Form 10-K
Reporting period: Fiscal year ended June 30, 2023. Although the request metadata says “2022 Q4,” the supplied filing is the company’s FY2023 annual report, not a standalone quarterly filing.
Business context and performance
Clorox is a multinational consumer and professional products company with FY2023 net sales of approximately $7.4 billion and about 8,700 employees. Its four reportable segments are Health and Wellness, Household, Lifestyle, and International. The company recast prior periods to move Vitamins, Minerals and Supplements (VMS) from Health and Wellness to Corporate and Other.
Management cited inflation, supply-chain recovery, higher manufacturing and logistics costs, and unfavorable foreign exchange as key factors in a dynamic operating environment. Sales growth was primarily attributed to cost-justified pricing and continued consumer demand for cleaning products and household essentials.
Key financial metrics
| Metric | FY2023 information in supplied text |
|---|---|
| Net sales | Approximately $7.4 billion, up 4% year over year. |
| Profit and EPS | Diluted net earnings per share decreased 68% year over year. The supplied text does not provide a clear net income, operating income, or diluted EPS value. |
| Impairment | $445 million noncash VMS impairment charge, or $362 million after tax. |
| Margins | Management said gross margin rebuilt; a margin percentage or dollar value is not provided in the supplied text. |
| Cash flow and liquidity | Specific cash-flow, cash-balance, and liquidity figures are not provided in the supplied text. |
| Debt | Approximately $2.5 billion as of June 30, 2023. |
| Dividends | $583 million paid during FY2023. In July 2023, the company announced a 2% quarterly dividend increase, its 21st consecutive annual increase. |
| Environmental remediation | Recorded liability of $28 million at June 30, 2023, unchanged from 2022. |
Changes versus the prior comparable period
- Net sales rose 4%, while diluted EPS fell 68%; management attributed much of the EPS decline to the VMS impairment, alongside digital-transformation and operating-model investments.
- The company reported gross-margin recovery, supported by pricing and cost savings, despite continued inflationary and supply-chain pressures.
- Walmart and its affiliates represented 26% of consolidated sales, versus 25% in each of FY2022 and FY2021.
- Cleaning products remained 42% of sales; bags and wraps were 16%, food products 11%, and cat litter 10% in FY2023.
Outlook, risks, and unusual items
- For FY2024, Clorox said it would continue investing in brands and capabilities to pursue consistent, profitable growth. The supplied text does not provide quantified FY2024 sales, earnings, or cash-flow guidance.
- The company expects volatility in commodity and transportation costs and inflationary pressures to continue into FY2024. Its ability to recover costs through pricing may be constrained by volume declines, competition, and lower-priced private-label products.
- A streamlined operating model began in FY2023. Management expects annual savings of approximately $75 million to $100 million once fully implemented; about $35 million of benefits were realized in FY2023.
- Clorox plans approximately $500 million of digital-transformation investment over five years, begun in FY2022. The filing identifies execution, system migration, and cybersecurity risks.
- The Glad venture agreement with Procter & Gamble expires in January 2026 unless extended. Clorox is required to purchase P&G’s 20% interest for cash at fair value; the estimated fair value was $527 million at June 30, 2023, while $495 million was recognized as a liability.
- Other material risks include dependence on major retailers, raw-material and supply-chain disruptions, foreign-exchange exposure, product and regulatory claims, and potential environmental liabilities. The filing says routine litigation is not expected to have a material adverse effect overall, while noting that outcomes remain uncertain.
Important facts for investors to verify
- Review Exhibit 99.1 for the complete audited statements and MD&A: detailed profit, margins, operating cash flow, cash and current liabilities are not included in the supplied filing text.
- Check the impairment’s accounting and segment effects, and the revised presentation of VMS in Corporate and Other.
- Assess the assumptions behind FY2024 cost recovery, continued pricing, and the $75 million to $100 million operating-model savings target.
- Evaluate the Glad repurchase obligation and the potential cash requirement at or before the January 2026 agreement expiration.
- Monitor debt, liquidity, and credit-rating disclosures, particularly given the company’s stated exposure to higher borrowing costs and derivative collateral provisions.